Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study

• Luigi Gargiulo,
• Luciano Ibba,
• Matteo Bianco,
• Sara Di Giulio,
• Alfano Alfano,
• Ruggero Cascio Ingurgio,
• Paola Facheris,
• Chiara Perugini,
• Mario Valenti,
• Antonio Costanzo,
• Alessandra Narcisi

Affiliations

Luigi Gargiulo

Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

Luciano Ibba

Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

Matteo Bianco

Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

Sara Di Giulio

Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

Alfano Alfano

Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

Ruggero Cascio Ingurgio

Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

Paola Facheris

Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

Chiara Perugini

Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

Mario Valenti

Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

Antonio Costanzo

Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy

Alessandra Narcisi

Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy